And for the pharmaceutical giants behind WEGOVY and ZEPBOUND, two of the best-selling drugs in modern history, the oral revolution is both their biggest opportunity and their greatest competitive threat
Retatrutide (LY3437943) is a synthetic triple agonist of GLP-1, GIP, and glucagon receptors developed by Eli Lilly, enabling simultaneous modulation of appetite, glycemic control, energy expenditure, and lipid metabolism
This leads to: Its essential to remember that weight loss medications, such as Wegovy, are not intended to replace healthy lifestyle choices, including a balanced diet and regular exercise
Degraded peptides can still appear clear
References Strong, L
What the Research Says So Far The research into GLP-1 patches is still early but compelling